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Title:  Change in practice over four decades in the management of Graves’ disease in Scotland  
Abstract 
There is continuing debate on the optimal treatment for Grave’s thyrotoxicosis with a resultant 
variation in clinical practice.  The present study aimed to ascertain changes in practice in the 
treatment of Grave’s thyrotoxicosis in Tayside, Scotland, over the past four decades. 
Methods 
The “Scottish automated follow-up register” (SAFUR) was queried to identify all patients treated 
for Grave’s thyrotoxicosis from 1968 to 2007 inclusive.  Patients were divided into 4 groups 
(group-A to D) according to the decades.  Demographic profile, treatment modalities, radio-
active iodine (RAI) dose, and recurrence rates were studied and outcomes compared by X2 test, 
and ANOVA using SPSS v15.0.  A p value of < 0.05 was considered significant. 
Results 
Altogether, 3737 patients were diagnosed with Grave’s thyrotoxicosis over the 4 decades. Use of 
RAI has increased from 43.1% in Group-A to 68% in Group-D (p<0.001). The dose of RAI has 
increased (p<0.001) and there has been a reduction in recurrence rate with higher dose of RAI. 
Surgical intervention rates decreased from 55.3% to 12.3% (p<0.001) over time.  
Conclusions 
Analysis of a large dataset of patients with Grave’s thyrotoxicosis suggests increasing use of RAI 
as the preferred first line of treatment.  Furthermore, using a single higher dose of RAI and 
adoption of total thyroidectomy has decreased recurrence rates. 
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Introduction 
Graves’ thyrotoxicosis, an autoimmune thyroid disorder affecting about 0.5% of the population, 
is the most common cause of diffuse toxic goiter.1  It accounts for 60 to 80% of patients with 
hyperthyroidism and shows a female preponderance with a female: male ratio of 10: 1.2  The 
three distinct treatment modalities (anti-thyroid drugs (ATD), radio-active iodine (131I) therapy 
(RAI) or surgery (total, sub-total or partial thyroidectomy) commonly used in the treatment of 
Graves’ thyrotoxicosis are either used singularly or in variable combinations depending on 
circumstances including disease characteristics and response to initial treatment.  The choice of 
optimal initial therapy for a patient with newly diagnosed Graves’ thyrotoxicosis is influenced by 
multiple factors and this may include patient/disease related factors, physician related factors, 
and system related factors such as cost.3 4 Furthermore, cultural and geographical influences are 
also thought to play a role in the choice of initial treatment offered to and accepted by patients.5   
The prevailing differences in treatment preferences for Graves' thyrotoxicosis have been 
highlighted by surveys conducted in America, Europe and Japan.5  In addition, studies have 
reported a similar early outcome of the disease, irrespective of the initial treatment modality 
used.  However, there was a clear difference in the relapse rate with different treatment; surgery 
producing the lowest relapse rates and anti-thyroid drugs producing the highest.6 The linear 
association between RAI dosage and remission rates has been investigated and recorded 
previously.7  Furthermore, there is currently no consensus on the best surgical option to treat 
Grave's thyrotoxicosis.  
Given the continuing debate on the optimal index therapy for Graves' thyrotoxicosis, in the 
current study, we investigated the time-trends in the choice of initial therapy used for a large 
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cohort of patients with newly diagnosed Graves' thyrotoxicosis over a period of four decades.  
We also sought to establish the remission rates with different treatment modalities including 
variable doses of RAI and different types of surgery that was used over the forty-year study 
period.   
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 Methods 
"Scottish automated follow-up register" (SAFUR) is a computer-based, shared-care (between 
primary care and hospital clinic) facility for automated follow-up of patients diagnosed with 
thyroid disorders including hyperthyroidism in Scotland.8  SAFUR has been available for clinical 
use since 1968 and currently has more than 20,000 patients registered on the database.  In 
Tayside, Scotland, over the past two decades, a well-defined clinical pathway exists for the care 
of patients with endocrine disorders including Grave's thyrotoxicosis.  All patients with thyroid 
disorders referred by the general practitioner to the hospital are first seen by a medical 
endocrinologist who initiates the necessary investigations and appropriate treatment from a 
hospital based thyroid clinic.  Patients are referred to an endocrine surgeon by the medical 
endocrinologist for consideration of operative treatment based on their clinical response.  Post 
surgical follow-up in the initial one year after surgery is by the surgical endocrine team and 
beyond one year further long-term follow-up will be led by the medical endocrine team.  Patients 
are re-referred to the surgeons for any surgical related problems.  At initial diagnosis patients are 
registered into the SAFUR database, a nation-wide follow-up registry which has an automated 
function for periodic call back of patients for surveillance blood checks at pre-determined times.  
The test results are reviewed and modifications to treatment based on the test results are made by 
the hospital based SAFUR medical endocrinology team.   
From the SAFUR database, we identified all patients who were newly diagnosed with Grave’s 
thyrotoxicosis in Tayside health board region, Scotland (estimated 2010 mid-year population of 
402,641) during the period 1968 - 2007 inclusive.  Diagnosis of Graves’ disease was based on 
clinical findings and elevated free T4 with or without an isotope scan.  Patients with toxic 
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adenoma or toxic multi-nodular goitre causing thyrotoxicosis were excluded.  For each patient 
the demographic data (age, gender) and clinical data including treatment data (index treatment, 
second treatment, use of RAI, dose of RAI used, use of surgery, and surgical technique 
employed) was collated.  Age at diagnosis was calculated from the date of receiving first 
treatment.  We determined the remission and recurrence rates based on the serum TSH levels 
recorded in the SAFUR database. For the study purposes, any normal or increased TSH level 
after index treatment was considered as remission.  Patients who received a second treatment and 
suppressed THS level after a period of euthyroidism or hypothyroidism were considered to have 
a clinically significant recurrence.   
Patients were divided into four groups according to the decade studied (group A= 1968–1977; 
group B=1978-1987; group C= 1988-1997; and group D= 1998-2007) and outcome measures 
were compared between the four groups to identify any time trends.  RAI dose was grouped in 
five different levels (<185 MBq, 185-369 MBq, 370-554MBq, 555-740MBq and >740MBq).  
Age is presented as mean ± SD.  Recurrence rates are presented as percentages.  The data was 
analysed using SPSS software (Statistical Package for the Social Sciences version 15·0, SPSS 
Inc., Chicago, IL, USA) and comparisons made using X2 test and ANOVA.  A p-value of < 0.05 
was considered significant.   
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Results: 
Baseline characteristics: 
Between 1968 and 2007, 3737 patients were diagnosed with Graves’ disease in Tayside health 
board region of Scotland.  The number of newly registered patients with a diagnosis of Graves’ 
disease increased with each decade of the study period; Group-A representing the first decade 
from 1968 to1977 (n=436); Group-B from 1978 to 1987 (n=755); Group-C from 1988 to 1997 
(n=1185); and Group-D representing the last decade from 1998 to 2007 (n=1361) (table 1).  
There was a female predominance (n=3155, 84.4%) in the whole study group with an overall 
female-to-male ratio of 5.4:1 (Table 1).  This preponderance of female patients was stable over 
the forty-year study period.   However, a statistically significant increase in the proportion of 
male patients diagnosed with Graves’ disease was noticed through the four decades (12.6% vs. 
16.8%: group A vs. group D; p=0.035) studied (Table 1).   
The mean age at diagnosis for the whole study group was 50 ± 16 years (Table 1).  The overall 
mean age of patients with Graves’ disease increased through the four decades and this was 
statistically significant (43 + 12 vs. 53 ± 17: group A vs. group D; p<0.001) (Table 1).  This 
increase in mean age was true when analysed by gender, with both males and females showing 
an increase through the four decades.  Figure 1 shows the age distribution for both genders and 
no difference in the mean age between genders were noticed over the four decades.   
Index therapy: 
The choice of index therapy used during the four decades is shown in Table 1.  Overall, anti-
thyroid drugs remained the least commonly used agent for initiating treatment after diagnosis 
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through the four decades.  However, its use as the first line agent almost doubled in the last 
decade.  In the first decade nearly half of the patients (48.2%) received surgery as the first line 
treatment.  However, a progressive decline in the use of surgery is recorded through the decades 
with only 11.6% patients undergoing surgery as principal treatment for Graves’ disease in the 
last decade.  This is in contrast to the gradual increase in the use of RAI (36% vs. 67.3%: group 
A vs. group D) over the four decades.  The combined use of surgery with post-operative RAI 
ablation also saw a decline (7.1% vs. 0.7%: group A vs. group D) through the four decades 
(Table 1).  This shift from surgical to medical treatment was found to be statistically significant 
(p<0.001).  
Surgery as index treatment: 
The mean age of patients who had surgical treatment as index therapy was 37.5 ± 13.5 years.  
Figure 2 shows the age distribution of patients receiving surgery.  The operation of choice during 
the first two decades (Group A and B) was subtotal thyroidectomy.  The surgical practice 
changed in 1992 to near total or total thyroidectomy.  Consequently, group C and D patients had 
either near total or total thyroidectomy.  There was a downward trend in the recurrence rates 
after surgical treatment (11.4% vs. 3%: group A vs. group D) over the decades and this trend is 
likely to reflect the change in surgical practice from sub-total thyroidectomy to total 
thyroidectomy (Table 2).  The mean time from surgical treatment to recurrence was 127 ± 91 
months (range 4-338 months).  On the other hand, the rate of postoperative hypothyroidism 
increased from 75% (Group A and B) to 96.4% (Group C and D) reflecting the use of total 
thyroidectomy as the preferred surgical technique. 
RAI as index treatment: 
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Patients who received treatment with RAI had a mean age of 55 ± 14.5 years.  Figure 3 
demonstrates the age distribution of patients receiving RAI as primary treatment.  The use of 
RAI as index therapy increased through the decades from 36% in the first decade (group A) to 
around 70% in the last two decades (group C and group D) (Table 1) of the study period.  
Altogether 2358 patients had RAI but information on dose of RAI used was available for 2237 
(94.9%) patients only.  There was a trend towards usage of higher doses of RAI over the time 
(p<0.001).  This was associated with a concurrent reduction in recurrence rates following RAI 
ablation therapy (p<0.001) (Figure 4).  The complete remission rate following RAI treatment 
was 92.8% with 7.2% patients having recurrence following RAI treatment.  This recurrence rate 
is comparable to the overall recurrence rate of 6.3% following surgical treatment in the study.  
Only 8.6% of patients, however, treated with ATD’s showed a complete remission.  
A second dose of RAI was administered to 158 patients with a mean dose of 602.8 ± 222.5 MBq.  
Thyroxine replacement was required in 87.2% of patients (n= 2358) following RAI therapy, a 
figure that was comparable to the rates of postoperative hypothyroidism seen in patients treated 
surgically.  The rate of post-treatment hypothyroidism was independent of the RAI dose at long-
term follow up (Table 3). 
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Discussion 
Treatment approaches to Grave’s disease differ, but ultimately is dependent on age, existing co-
morbidities, and preference of patients and clinicians.  Although most clinicians would 
recommend anti-thyroid drugs (ATD) as the first line therapy,1 variations in practice have been 
recorded between Europe, Asia and America. 9 Whilst, in America, ATD are used as an adjunct 
prior to index treatment with RAI or surgery,5 in Europe and Asia ATD are primarily employed 
as the initial therapy for newly diagnosed cases with RAI or surgery offered as second-line 
treatment for those patients who relapse on ATD. Surgical treatment may be the preferred option 
for many patients as it provides immediate symptomatic relief, does not require frequent 
monitoring of thyroid function since the inevitable hypothyroidism is treated with hormone 
replacement therapy, and interferes less with patients’ complex lifestyles.4 Furthermore, recent 
cost-effectiveness studies have demonstrated that thyroidectomy might be more cost-effective 
than RAI or ATDs, without compromising quality of life.10-12 
In view of the controversies in the management of GD, this study, one of the largest to date, 
attempted to summarise, compare and contrast the management of patients with Graves’ 
thyrotoxicosis in a health authority in Scotland over a period of four decades.  
Anti-thyroid medication was consistently the least popular definitive treatment modality 
probably due to its associated high recurrence rate.  The reported remission rate with ATDs is 
around 40%-50%9 but in our long term series, it was only 8.6%. Furthermore, lifelong ATD 
therapy necessitates frequent thyroid function monitoring and is associated with life-threatening 
side effects such as agranulocytosis and hepatotoxicity.13 Surprisingly, the use of ATDs almost 
doubled in the last decade (Table 1), which is difficult to explain, but may be related to the 
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increasing age of patients diagnosed with Graves’ disease. Older patients may be more likely to 
opt for conservative management and younger patients for surgery since the mean age of patients 
who had surgery as index therapy was 37.5 years. This is supported by other studies who 
reported that patient preference was the most common indication for thyroidectomy.4  
Another interesting trend identified regarding the choice of therapy was the significant decline in 
the use of thyroidectomy alone or in combination with RAI and the impressive increase in the 
use of RAI. This is likely to be the result of the increasing willingness to utilize RAI because of 
its safety, the ease and convenience of administration, its lower cost and increasing acceptance 
by patients.3 5 9 14 Furthermore, RAI has similar remission and post-treatment hypothyroidism 
rates to thyroidectomy. Despite RAI becoming the first line of definitive therapy in Graves’ 
disease, there is lack of consensus regarding optimal treatment dose.1 Treatment with adjusted 
RAI dose has failed to prove superiority over fixed standard dose regimen.15 16 In our study, 
remission rate with a dose of 370-740MBq is higher (~93%) to that of other published studies.17 
18 However, an increased rate of remission (96.2%) has been achieved with a dose of >740MBq 
(741-1110MBq) and is similar to that reported in another study.7 Furthermore, the rate of 
hypothyroidism is fairly common in all groups and not directly related to the RAI dose.  
Despite its large sample size obtained from a national registry our study has the following 
limitations. The Scottish national statistics reported an increase in the mid-term population of the 
Tayside health board region (e.g. mid-term population; 1981 vs. 2010 - 397,055 vs. 402,641) 
during the four decades of study period. However, as the geographical region covered by the 
Tayside health board underwent reorganisation during this period, we were unable to calculate 
the true changes in population-based incidence of Grave’s disease for the region. Despite it being 
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a prospective registry not all data was available for the use of RAI, and particularly for the RAI 
dosage. The final analysis reported in the study used the available dataset. Furthermore, the 
scope of the study was limited to a single health board region with all the comparisons made 
being ‘within study’ comparisons to ascertain changes with time through the four decades 
studied. No attempt was made to compare the health board data with the national data, as this 
was not available for the study group at the time of the study. 
In conclusion, the treatment of Graves’ disease in a Scottish Health Authority has evolved over 
the last 40 years favouring the early use of RAI in almost 70% of patients. This is compatible 
with common practice in the United States where the vast majority of patients are treated with 
RAI with or without ATDs.  A higher dose of radiation (>740MBq) is recommended to prevent 
recurrence and achieve remission.  Further development of clinical pathways should be informed 
by the outcomes of this longitudinal observational study. 
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Table 1: Demographic characteristics and index therapy according to decades 
 
 Whole study 1968 - 2007 
Group A 
1968 - 1977 
Group B 
1978 - 1987 
Group C 
1988 - 1997 
Group D 
1998 - 2007 
Total number of GT 
patients (%) 3737 (100%) 436 (11.7%) 755 (20.2%) 1185 (31.7%) 1361 (36.4%) 
Gender distribution  
Females (%) 3155 (84.4%) 381 (87.4%) 642 (85%) 1000 (84.4%) 1132 (83.2%) 
Males (%) 582 (15.6%) 55 (12.6%) 113 (15%) 185 (15.6%) 229 (16.8%) 
Female : Male 5.4: 1 6.9: 1 5.7: 1 5.4: 1 4.9: 1 
Overall age 
Mean + Std Dev 50 + 16 43 + 12 47 + 15 51 + 16 53 + 17 
Age of females 
Mean + Std Dev 50 + 16 43 + 12 47 + 15 51 + 16 53 + 17 
Age of males 
Mean + Std Dev 51 + 16 41 + 13 49 + 14 50 + 17 54 + 16 
Index treatment 
used  
Anti-thyroid drugs 320 (8.6%) 27 (6.2%) 47 (6.2%) 76 (6.4%) 170 (12.5%) 
Radio-active iodine 2274 (60.1%) 157 (36%) 371 (49.1%) 830 (70%) 916 (67.3%) 
Surgery 873 (23.4%) 210 (48.2%) 293 (38.8%) 212 (17.9%) 158 (11.6%) 
Surgery + RAI 87 (2.3%) 31 (7.1%) 28 (3.7%) 18 (1.5%) 10 (0.7%) 
 
GT: Graves’ thyrotoxicosis; Std Dev: Standard deviation; RAI: Radio-active iodine 
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Table 2: Outcomes after thyroidectomy according to decade 
 Total number of 
patients  
(%) 
Remission rate 
(%) 
Recurrence rate 
(%) 
Group A  
(1968-1977) 241 (55%) 214 (89%) 11.4% 
Group B  
(1978-1987) 321 (43%) 295 (92%) 7.3% 
Group C  
(1988-1997) 229 (19%) 217(95%) 3.2% 
Group D  
(1998-2007) 167(12%) 167(97%) 3% 
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Table 3: Outcome after different RAI dose 
RAI dose Remission n (%) 
Recurrence 
n (%) 
Hypothyroidism 
n (%) Total 
<185 MBq 5 (62.5) 3 (37.5) 5(62.5) 8 
185-369 MBq 244 (82.7) 51(17.3) 265(89.8) 295 
370-554MBq 1046 (93.5) 73 (6.5) 989(88.4) 1119 
555-740MBq 74 (93.7) 5 (6.3) 70(88.6) 79 
>740MBq 708 (96.2) 28 (3.8) 617(83.8) 736 
Total 2077 (92.8) 160 (7.2) 1946(86.9) 2237 
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Figure 1: Age distribution of patients with Graves’ disease 
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Figure 2: Age distribution of patients who underwent surgery 
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Figure 3: Age distribution of patients who had RAI treatment 
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Figure 4: Recurrence rate in relation to RAI dose 
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